NCT06267846 - A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Major Depressive Disorder

Interventions

DRUG

NBI-1070770

Suspension for oral administration

DRUG

Placebo

Suspension for oral administration

Trial Locations (13)

Neurocrine Clinical Site, Gaithersburg

Neurocrine Clinical Site, Decatur

Neurocrine Clinical Site, Savannah

Neurocrine Clinical Site, Maitland

Neurocrine Clinical Site, Hollywood

Neurocrine Clinical Site, North Canton

Neurocrine Clinical Site, Dayton

Neurocrine Clinical Site, Little Rock

Neurocrine Clinical Site, Rogers

Neurocrine Clinical Site, Richardson

Neurocrine Clinical Site, Houston

Neurocrine Clinical Site, Long Beach

Neurocrine Clinical Site, Lemon Grove